株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

PharmaPoint:黄斑浮腫 (ME) と黄斑変性症 (MD) - EU5ヶ国の医薬品市場の2023年までの予測と市場分析

PharmaPoint: Macular Edema and Macular Degeneration - 5EU Drug Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 325947
出版日 ページ情報 英文 274 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
PharmaPoint:黄斑浮腫 (ME) と黄斑変性症 (MD) - EU5ヶ国の医薬品市場の2023年までの予測と市場分析 PharmaPoint: Macular Edema and Macular Degeneration - 5EU Drug Forecast and Market Analysis to 2023
出版日: 2014年10月31日 ページ情報: 英文 274 Pages
概要

黄斑浮腫 (ME) は、液体が黄斑に貯留した状態で、視力障害を引き起こしたり、重症例では失明にいたることもあります。加齢性黄斑変性症 (AMD) は、痛みのない眼疾患で、段階的、不可逆的に中心視力が低下し、50歳以上の、先進国の人々の主な失明原因の1つになっています。

当レポートでは、EU5ヶ国の黄斑浮腫 (ME) と黄斑変性症 (MD) の治療薬市場について調査分析し、疾患の概要とガイドライン、競合情勢、主要薬剤の詳細情報 (製品説明、安全性、有効性) 、SWOT分析、売上高予測、影響分析 (動向、促進要因・抑制要因) などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 黄斑変性症 (MD) の概要
  • 黄斑浮腫 (ME) の概要

第4章 疾患の管理

  • 診断と治療の概要
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国

第5章 競合評価

  • 概要
  • 製品プロファイル:主要ブランド

第6章 アンメットニーズと機会

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望な薬剤
  • 初期開発中の有望な薬剤
  • その他の開発中の薬剤
  • バイオシミラー

第8章 市場の見通し

  • 世界市場
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国

第9章 付録

図表

目次
Product Code: GDHC262CFR

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

The new therapies entering the AMD market will be the main driver of growth in this market, with the wAMD drugs Fovista, squalamine, and abicipar pegol launching into the French market in 2017, 2018, and 2020, respectively. GlobalData estimates that the combined drug sales for ME and AMD in Italy during 2013 reached $348m.

Scope

  • Overview of Macular Edema and Macular Degeneration including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in 5EU from 2013-2023.
  • Analysis of the impact of key events as well the drivers and restraints affecting 5EU Macular Edema and Macular Degeneration market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2013-2023 in 5EU.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Related Reports

3. Disease Overview

  • 3.1. Macular Degeneration Overview
    • 3.1.1. Etiology and Pathophysiology
    • 3.1.2. Classification
    • 3.1.3. Symptoms and Diagnosis
  • 3.2. Macular Edema Overview
    • 3.2.1. Etiology and Pathophysiology
    • 3.2.2. Classification
    • 3.2.3. Symptoms and Diagnosis

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Macular Edema Diagnosis
    • 4.1.2. Macular Degeneration Diagnosis
    • 4.1.3. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.4. Clinical Practice
  • 4.2. France
  • 4.3. Germany
  • 4.4. Italy
  • 4.5. Spain
  • 4.6. UK

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Product Profiles - Major Brands
    • 5.2.1. Lucentis (ranibizumab)
    • 5.2.2. Eylea (aflibercept)
    • 5.2.3. Avastin (bevacizumab)
    • 5.2.4. Macugen (pegaptanib sodium)
    • 5.2.5. Visudyne (verteporfin)
    • 5.2.6. Corticosteroid Implants

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Treatment for Dry AMD
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Longer-Acting Anti-VEGF Drug Therapy
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Increased Efficacy of Anti-VEGF Therapy for wAMD
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Less Invasive Drug Formulations
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Awareness and Earlier Patient Diagnosis
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Home Monitoring of AMD Progression
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Abicipar pegol
    • 7.2.2. Fovista
    • 7.2.3. Squalamine
    • 7.2.4. Lampalizumab
    • 7.2.5. Emixustat
  • 7.3. Promising Drugs in Early-Stage Development
    • 7.3.1. Complement Inhibitors
  • 7.4. Other Drugs in Development
  • 7.5. Biosimilars

8. Market Outlook

  • 8.1. Global
    • 8.1.1. Drivers and Barriers - Global Issues
  • 8.2. France
    • 8.2.1. Forecast
    • 8.2.2. Key Events
    • 8.2.3. Drivers and Barriers
  • 8.3. Germany
    • 8.3.1. Forecast
    • 8.3.2. Key Events
    • 8.3.3. Drivers and Barriers
  • 8.4. Italy
    • 8.4.1. Forecast
    • 8.4.2. Key Events
    • 8.4.3. Drivers and Barriers
  • 8.5. Spain
    • 8.5.1. Forecast
    • 8.5.2. Key Events
    • 8.5.3. Drivers and Barriers
  • 8.6. UK
    • 8.6.1. Forecast
    • 8.6.2. Key Events
    • 8.6.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed ME and AMD Patients
    • 9.4.2. Percentage of Drug-Treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Pricing of Pipeline Agents
  • 9.5. Primary Research - KOLs Interviewed for this Report
  • 9.6. Primary Research - High-Prescribers Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Therapy Area Director
    • 9.7.3. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: ARM System Classification of AMD
  • Table 2: Symptoms of AMD
  • Table 3: National and International Treatment Guidelines for ME and AMD
  • Table 4: Most Prescribed Drugs for ME and AMD in the 5 EU Markets, 2013
  • Table 5: ME and AMD Disease Management - France
  • Table 6: ME and AMD Disease Management - Germany
  • Table 7: ME and AMD Disease Management - Italy
  • Table 8: ME and AMD Disease Management - Spain
  • Table 9: ME and AMD Disease Management - UK
  • Table 10: Leading Treatments for ME and AMD, 2014
  • Table 11: Product Profile - Lucentis
  • Table 12: Lucentis SWOT Analysis, 2014
  • Table 13: Approval Dates for Eylea
  • Table 14: Product Profile - Eylea
  • Table 15: Eylea - Common Adverse Reactions
  • Table 16: Eylea SWOT Analysis, 2014
  • Table 17: Product Profile - Avastin
  • Table 18: Avastin SWOT Analysis, 2014
  • Table 19: Product Profile - Macugen
  • Table 20: Product Profile - Visudyne
  • Table 21: Visudyne SWOT Analysis, 2014
  • Table 22: Product Profile - Ozurdex
  • Table 23: Product Profile - Iluvien
  • Table 24: Corticosteroid IVT Implants SWOT Analysis, 2014
  • Table 25: Unmet Needs and Opportunities in ME and AMD
  • Table 26: Promising Drugs in Clinical Development for ME and AMD
  • Table 27: Comparison of Drugs in Development for ME and AMD, 2014
  • Table 28: Product Profile - Abicipar pegol
  • Table 29: SWOT Analysis - Abicipar pegol, 2014
  • Table 30: Product Profile - Fovista
  • Table 31: SWOT Analysis - Fovista, 2014
  • Table 32: Product Profile - Squalamine
  • Table 33: SWOT Analysis - Squalamine, 2014
  • Table 34: Product Profile - Lampalizumab
  • Table 35: SWOT Analysis - Lampalizumab, 2014
  • Table 36: Product Profile - Emixustat
  • Table 37: SWOT Analysis - Emixustat, 2014
  • Table 38: Early-Stage Drugs in Clinical Development for ME and AMD, 2014
  • Table 39: ME and AMD Markets - Drivers and Barriers, 2013-2023
  • Table 40: Sales Forecast ($m) for ME in France, 2013-2023
  • Table 41: Sales Forecast ($m) for AMD in France, 2013-2023
  • Table 42: Key Events Impacting Sales for ME and AMD in France, 2013-2023
  • Table 43: ME and AMD Markets - Drivers and Barriers in France, 2013-2023
  • Table 44: Sales Forecast ($m) for ME in Germany, 2013-2023
  • Table 45: Sales Forecast ($m) for AMD in Germany, 2013-2023
  • Table 46: Key Events Impacting Sales for ME and AMD in Germany, 2013-2023
  • Table 47: ME and AMD Markets - Drivers and Barriers in Germany, 2013-2023
  • Table 48: Sales Forecast ($m) for ME in Italy, 2013-2023
  • Table 49: Sales Forecast ($m) for AMD in Italy, 2013-2023
  • Table 50: Key Events Impacting Sales for MME and AMD in Italy, 2013-2023
  • Table 51: ME and AMD Markets - Drivers and Barriers in Italy, 2013-2023
  • Table 52: Sales Forecast ($m) for ME in Spain, 2013-2023
  • Table 53: Sales Forecast ($m) for AMD in Spain, 2013-2023
  • Table 54: Key Events Impacting Sales for ME and AMD in Spain, 2013-2023
  • Table 55: ME and AMD Markets - Drivers and Barriers in Spain, 2013-2023
  • Table 56: Sales Forecast ($m) for ME in the UK, 2013-2023
  • Table 57: Sales Forecast ($m) for AMD in the UK, 2013-2023
  • Table 58: Key Events Impacting Sales for ME and AMD in the UK, 2013-2023
  • Table 59: ME and AMD Markets - Drivers and Barriers in the UK, 2013-2023
  • Table 60: Key Launch Dates
  • Table 61: Key Patent Expiries
  • Table 62: Surveyed High-Prescribing Physicians (Non-KOLs), by Country

List of Figures

  • Figure 1: Anatomy of the Eye and Macula
  • Figure 2: Amsler Grid viewed by Patient with Normal Vision and with wAMD
  • Figure 3: Color Fundus Photographs of Dry and Wet AMD
  • Figure 4: FAF Imaging of GA
  • Figure 5: Imaging of wAMD
  • Figure 6: CMT in DME
  • Figure 7: RVOs (BRVO and CRVO) on an FA
  • Figure 8: Increased CRT in ME-RVO
  • Figure 9: ME Clinical Treatment Flowchart
  • Figure 10: AMD Clinical Treatment Flowchart
  • Figure 11: Eylea's Clinical Development in DME and ME-BRVO
  • Figure 12: Iluvien's and Ozurdex's Clinical Development in wAMD, dAMD, and DME
  • Figure 13: Competitive Assessment of Late-Stage Pipeline Agents in ME and AMD, 2013-2023
  • Figure 14: Abicipar Pegol's Clinical Development in wAMD and DME
  • Figure 15: Clinical and Commercial Positioning of abicipar pegol
  • Figure 16: Fovista's Clinical Development in wAMD
  • Figure 17: Clinical and Commercial Positioning of Fovista
  • Figure 18: Squalamine's Clinical Development in wAMD and DME
  • Figure 19: Clinical and Commercial Positioning of squalamine
  • Figure 20: Lampalizumab's Development in wAMD
  • Figure 21: Clinical and Commercial Positioning of lampalizumab
  • Figure 22: Emixustat Clinical Development in dAMD
  • Figure 23: Clinical and Commercial Positioning of emixustat
  • Figure 24: Individual Drug Sales for ME in France, 2013-2023
  • Figure 25: Individual Drug Sales for AMD in France, 2013-2023
  • Figure 26: Individual Drug Sales for ME in Germany, 2013-2023
  • Figure 27: Individual Drug Sales for AMD in Germany, 2013-2023
  • Figure 28: Individual Drug Sales for ME in Italy, 2013-2023
  • Figure 29: Individual Drug Sales for AMD in Italy, 2013-2023
  • Figure 30: Individual Drug Sales for ME in Spain, 2013-2023
  • Figure 31: Individual Drug Sales for AMD in Spain, 2013-2023
  • Figure 32: Individual Drug Sales for ME in the UK, 2013-2023
  • Figure 33: Individual Drug Sales for AMD in the UK, 2013-2023
Back to Top